Journal
BLOOD
Volume 117, Issue 17, Pages 4615-4622Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-08-303677
Keywords
-
Categories
Funding
- Fund for Scientific Research-Flanders (FWO-Vlaanderen) [6.0833.09]
- Agency for the Promotion and Innovation through Science and Technology in Flanders (IWT-Vlaanderen)
Ask authors/readers for more resources
The enhancement of fibrinolysis constitutes a promising approach to treat thrombotic diseases. Activated thrombin activatable fibrinolysis inhibitor (TAFIa) attenuates fibrinolysis and is an attractive target to develop profibrinolytic drugs. TAFI can be activated by thrombin, thrombin/thrombomodulin, or plasmin, but the in vivo physiologic TAFI activator( s) are unknown. Here, we generated and characterized MA-TCK26D6, a monoclonal antibody raised against human TAFI, and examined its profibrinolytic properties in vitro and in vivo. In vitro, MA-TCK26D6 showed a strong profibrinolytic effect caused by inhibition of the plasmin-mediated TAFI activation. In vivo, MA-TCK26D6 significantly decreased fibrin deposition in the lungs of thromboembolism-induced mice. Moreover, in the presence of MA-TCK26D6, plasmin-alpha(2)-antiplasmin complexes in plasma of thromboembolism-induced mice were significantly increased compared with a con-trol antibody, indicative of an acceleration of fibrinolysis through MA-TCK26D6. In this study, we show that plasmin is an important TAFI activator that hampers in vitro clot lysis. Furthermore, this is the first report on an anti-TAFI monoclonal antibody that demonstrates a strong profibrinolytic effect in a mouse thromboembolism model. (Blood. 2011;117(17):4615-4622)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available